Replimune Group Quarterly Income Statement
NASDAQ: REPLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
19.07-0.16 (-0.83%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Replimune Group revenue and earnings
Replimune Group reported a net loss of $57.1 million, compared with a loss of $83.1 million a year earlier. Diluted earnings per share came in at -$0.54.
Summary generated from market data by MetaCap's automated system. Methodology
Replimune Group income statement (quarterly)
| Quarter (USD) | Q2 20272026-09-30 | Q1 20272026-06-30 | Q4 20262026-03-31 | Q3 20262025-12-31 | Q2 20262025-09-30 | Q1 20262025-06-30 | Q4 20252025-03-31 | Q3 20252024-12-31 | Q2 20252024-09-30 | Q1 20252024-06-30 | Q4 20242024-03-31 | Q3 20242023-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 56.28M | 68.25M | 73.34M | 71.87M | 84.29M | 90.42M | 79.33M | 66.02M | 58.92M | 57.37M | 58.76M | 56.54M |
| Research & Development | 34.37M | 49.28M | 52.32M | 53.14M | 57.88M | 57.84M | 53.98M | 48.00M | 43.45M | 42.97M | 42.58M | 42.85M |
| Selling, General & Admin | 21.92M | 18.97M | — | — | 26.41M | 32.58M | — | — | — | — | — | — |
| Operating Income | -56.28M | -68.25M | -73.34M | -71.87M | -84.29M | -90.42M | -79.33M | -66.02M | -58.92M | -57.37M | -58.76M | -56.54M |
| Interest Expense | 2.52M | 2.58M | 2.37M | 1.47M | 1.49M | 1.48M | 1.46M | 1.45M | 1.44M | 1.43M | 1.41M | 1.01M |
| Other Income (Expense) | -840.00K | -1.52M | -119.00K | 627.00K | 1.19M | 3.73M | 5.09M | 254.00K | 5.86M | 3.60M | 3.62M | 5.89M |
| Pretax Income | — | — | -73.46M | -71.24M | — | — | -74.24M | -65.77M | -53.05M | -53.77M | -55.14M | -50.65M |
| Income Tax | — | — | -240.00K | -311.00K | 0 | 0 | -107.00K | 575.00K | 0 | 0 | -65.00K | 473.00K |
| Net Income | -57.12M | -69.77M | -73.22M | -70.93M | -83.10M | -86.69M | -74.13M | -66.34M | -53.05M | -53.77M | -55.08M | -51.12M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.54 | -0.72 | -0.76 | -0.77 | -0.90 | -0.95 | -0.82 | -0.79 | -0.68 | -0.78 | -0.82 | -0.77 |
| EPS (Diluted) | -0.54 | -0.72 | -0.76 | -0.77 | -0.90 | -0.95 | -0.82 | -0.79 | -0.68 | -0.78 | -0.82 | -0.77 |
| Shares Outstanding (Basic) | 105.18M | 96.86M | — | 92.19M | 91.92M | 91.52M | — | 83.50M | 78.57M | 69.19M | — | 66.65M |
| Shares Outstanding (Diluted) | 105.18M | 96.86M | — | 92.19M | 91.92M | 91.52M | — | 83.50M | 78.57M | 69.19M | — | 66.65M |
| EBITDA | -55.48M | -67.31M | -72.57M | -71.07M | -83.49M | -89.55M | -78.48M | -65.02M | -58.02M | -56.63M | -58.05M | -55.84M |
This table shows 12 quarterly periods of Replimune Group's income statement, from Q2 2027 back to Q3 2024, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow REPL's reporting calendar. What is a income statement?